Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,374 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,072 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07126158 | Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma | recruiting | Phase 2 | 36 | Washington University School of MedicineOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05821556 | Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients | recruiting | Phase 2 | 240 | National Cancer Institute, NaplesOTHER | 2 | Apr 14, 2026 |
| clinicaltrials |
| NCT06485466 | TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma | recruiting | Phase 3 | 101 | Guohui XuOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04406831 | The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer | recruiting | — | 200 | Nuvance HealthOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05257590 | CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 95 | TaiRx, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05257993 | Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 71 | Onconic Therapeutics Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05745857 | Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas(SLURP) | recruiting | Phase 2 | 25 | University Medical Center GroningenOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06426992 | Clinical Effectiveness of Microwave Ablation Using Starwave Microwave Generator for Hepatic Malignancies | recruiting | N/A | 128 | Seoul National University HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06454383 | Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer | recruiting | Phase 1 | 19 | City of Hope Medical CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07114861 | The KN510713 Study in Combination With mFOLFIRINOX | recruiting | Phase 1 / Phase 2 | 30 | New Cancer Cure-Bio Co.,Ltd.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04624555 | The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors | recruiting | — | 50 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05927857 | Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . | recruiting | Phase 1 / Phase 2 | 45 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06955767 | Measurement of MMP-14 Protein, a Potential New Marker for Colorectal Cancer Detection, in Plasma Vesicles Named Exosomes(EXOSCOL02) | recruiting | N/A | 650 | CHU de ReimsOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07293468 | Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)(BIIRTH) | recruiting | Phase 2 / Phase 3 | 106 | Tuen Mun HospitalOTHER_GOV | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05624918 | A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma | recruiting | Phase 2 | 38 | Ashish ManneOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05753306 | Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study | recruiting | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05003895 | GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies | recruiting | Phase 1 | 38 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06639724 | Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer | recruiting | Phase 1 | 36 | University of California, San DiegoOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04622423 | Advanced Therapies for Liver Metastases(LiMeT) | recruiting | — | 625 | IRCCS San RaffaeleOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06850623 | Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer(ENACT) | recruiting | Phase 2 | 25 | EXACT Therapeutics ASINDUSTRY | 2 | Apr 3, 2026 | clinicaltrials |
| NCT05733598 | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | recruiting | Phase 2 | 60 | Replimune, Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06553885 | Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC | recruiting | Phase 2 | 40 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05514769 | Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty Versus Esophagogastric Anastomosis for Gastric Cancer | recruiting | N/A | 60 | Nanchong Central HospitalOTHER_GOV | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04703101 | Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer | recruiting | Phase 1 | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07144917 | Immunoparalysis After Pancreaticoduodenectomy(ImPaHLA) | recruiting | — | 100 | Hospices Civils de LyonOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07500220 | Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC(DUET-HCC) | recruiting | Phase 1 / Phase 2 | 30 | Beijing BiotechINDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06687941 | A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors | recruiting | Phase 1 | 70 | Aptamer Sciences, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07324096 | A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer(AI-PACED) | recruiting | N/A | 100 | Mayo ClinicOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07331883 | Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2) | recruiting | Phase 2 | 35 | Ruijin HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07495215 | A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection | recruiting | Phase 1 / Phase 2 | 20 | Yinghua XuOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05024214 | Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07493421 | To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement. | recruiting | N/A | 20 | Unidade Local de Saúde São JoãoOTHER_GOV | 2 | Mar 25, 2026 | clinicaltrials |
| NCT07089940 | OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Early Phase 1 | 12 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07466602 | cfDNA Methylation for Liver Cancer Recurrence Detection | recruiting | — | 500 | Wuhan Ammunition Life-tech Co., LtdINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06345508 | Early Detection of Liver Cancer by QUS(QUS in HCC) | recruiting | — | 328 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05629845 | Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients(EUS-SPV) | recruiting | N/A | 84 | Chinese University of Hong KongOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07482059 | A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 33 | West China HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06077591 | Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors(PDO) | recruiting | N/A | 40 | Chinese University of Hong KongOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480928 | Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma(DUAL-NK-PDAC) | recruiting | Phase 1 / Phase 2 | 42 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03384238 | Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery | recruiting | Phase 1 / Phase 2 | 27 | George PoultsidesOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06336902 | Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer | recruiting | Phase 1 | 15 | University of Southern CaliforniaOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04808323 | MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer | recruiting | Phase 1 | 22 | Medical College of WisconsinOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05528952 | Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma(TERTIO) | recruiting | Phase 2 | 105 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06555588 | Engage Psychosocial Intervention for Cancer Symptoms(Engage) | recruiting | N/A | 190 | Duke UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06756074 | Reinforced Pancreaticojejunostomy With or Without glubran2 | recruiting | Phase 2 | 100 | Minia UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07052253 | A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. | recruiting | Phase 2 | 100 | AkesoINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 15, 2026source: clinicaltrials